Traduction de «monthly reports containing financial information » (Néerlandais → Français) :

In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management receives a monthly analysis incorporating these core measures.
En plus des rapports mensuels contenant des informations financières préparées selon les normes IFRS (International Financial Reporting Standards), les cadres dirigeants reçoivent une analyse mensuelle intégrant ces mesures core.

In addition to monthly reports containing financial information prepared under International Financial Reporting Standards (IFRS), senior management will receive a monthly analysis incorporating these core measures.
En plus des rapports mensuels contenant des informations financières préparées selon les normes IFRS (International Financial Reporting Standards), les cadres dirigeants recevront une analyse mensuelle intégrant ces mesures «core».

These condensed consolidated financial statements for the three-month quarterly and the 12-month periods ended December 31, 2008, were prepared in accordance with International Accounting Standard 34 “Interim Financial Reporting” and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes consolidés simplifiés pour le trimestre et la période de douze mois se terminant le 31 décembre 2008 ont été établis conformément à la norme comptable internationale 34 concernant l’information financière intermédiaire (IAS 34 « Interim Financial Reporting ») et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

These Condensed Interim Consolidated Financial Statements for the three- and nine-month periods ended September 30, 2010, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010, except as indicated below.
Les comptes consolidés intermédiaires simplifiés pour les périodes de trois et neuf mois se terminant le 30 septembre 2010 ont été établis conformément à la norme comptable internationale IAS 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010, sauf indication contraire ci-dessous.

These Condensed Interim Consolidated Financial Statements for the three- and six-month periods ended June 30, 2010, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010, except as indicated below.
Les comptes consolidés intermédiaires simplifiés pour les périodes de trois et six mois se terminant le 30 juin 2010 ont été établis conformément à la norme comptable internationale IAS 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010, sauf indication contraire ci-dessous.

These Condensed Interim Consolidated Financial Statements for the three-month period ended March 31, 2010, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010, except as indicated below.
Les comptes consolidés intermédiaires simplifiés pour la période de trois mois se terminant le 31 mars 2010 ont été établis conformément à la norme comptable internationale IAS 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010, sauf indication contraire ci-dessous.

These Condensed Consolidated Financial Statements for the three- and twelve-month periods ended December 31, 2009, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2009 Annual Report published on January 26, 2010.
Les comptes intermédiaires consolidés simplifiés pour les périodes de trois et de douze mois se terminant le 31 décembre 2009 ont été établis conformément à la norme comptable internationale 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2009 publié le 26 janvier 2010.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.
Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.